Edition:
United Kingdom

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

5.17USD
23 May 2018
Change (% chg)

$0.06 (+1.17%)
Prev Close
$5.11
Open
$5.14
Day's High
$5.17
Day's Low
$5.03
Volume
26,882
Avg. Vol
236,421
52-wk High
$7.34
52-wk Low
$0.88

Chart for

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip... (more)

Overall

Beta: --
Market Cap(Mil.): $57.61
Shares Outstanding(Mil.): 27.70
Dividend: --
Yield (%): --

Financials

  VKTX.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.83 -- --
ROI: -183.94 1.57 14.38
ROE: -184.23 2.43 16.07

BRIEF-Viking Therapeutics Q1 Loss Per Share $0.08

* VIKING THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Viking Therapeutics Q4 Loss Per Share $0.14

* VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

07 Mar 2018

BRIEF-Viking Therapeutics - Pricing Public Offering Of 11 Mln Shares At $5 Per Share

* VIKING THERAPEUTICS ANNOUNCES PRICING OF $55.0 MILLION PUBLIC OFFERING OF COMMON STOCK

02 Feb 2018

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

01 Feb 2018

BRIEF-Sphera Funds Management Ltd Reports 7.43 Pct Passive Stake In Viking Therapeutics

* SPHERA FUNDS MANAGEMENT LTD REPORTS 7.43 PERCENT PASSIVE STAKE IN VIKING THERAPEUTICS INC AS OF DECEMBER 7 - SEC FILING Source text : http://bit.ly/2kdgndu Further company coverage:

18 Dec 2017

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

05 Dec 2017

BRIEF-Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture

* VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VK5211 IN PATIENTS RECOVERING FROM HIP FRACTURE

28 Nov 2017

Earnings vs. Estimates